Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Nov 6, 2024

Accession no.
0001447362-24-000175
Filed
Nov 6, 2024
Trade date
Nov 4, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 14 non-derivative transactions. Open-market sales total $166.8K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 4, 2024Common StockSSaleDisposed−1,943$32.53F2−$63,205.7989,721Direct
Nov 4, 2024Common StockSSaleDisposed−995$32.53F2−$32,367.3575,641Indirect
Nov 4, 2024Common StockSSaleDisposed−934$32.53F2−$30,383.0264,853Indirect
Nov 4, 2024Common StockSSaleDisposed−295$32.53F2−$9,596.356,465Indirect
Nov 4, 2024Common StockSSaleDisposed−294$32.53F2−$9,563.826,455Indirect
Nov 4, 2024Common StockSSaleDisposed−294$32.53F2−$9,563.826,455Indirect
Nov 4, 2024Common StockSSaleDisposed−294$32.53F2−$9,563.826,455Indirect
Nov 4, 2024Common StockSSaleDisposed−29$33.16−$961.6489,692Direct
Nov 4, 2024Common StockSSaleDisposed−15$33.16−$497.475,626Indirect
Nov 4, 2024Common StockSSaleDisposed−14$33.16−$464.2464,839Indirect
Nov 4, 2024Common StockSSaleDisposed−5$33.16−$165.86,460Indirect
Nov 4, 2024Common StockSSaleDisposed−5$33.16−$165.86,450Indirect
Nov 4, 2024Common StockSSaleDisposed−5$33.16−$165.86,450Indirect
Nov 4, 2024Common StockSSaleDisposed−5$33.16−$165.86,450Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $32.130 to $33.015, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)